41709-83-5

Basic information

• Product Name: 4-Methoxy-1H-Isoindole-1,3(2H)-dione
• Synonyms: 4-Methoxy-1H-Isoindole-1,3(2H)-dione;4-methoxy-isoindole-1,3-dione
• CAS NO: 41709-83-5
• Molecular Formula: C9H7NO3
• Molecular Weight: 177.15678
• Mol File: 41709-83-5.mol
• Article Data: 5

Chemical Properties

• Melting Point: 221-222 °C(Solv: methanol (67-56-1))
• Appearance: /
• Density: 1.346±0.06 g/cm3(Predicted)
• PKA: 9.89±0.20(Predicted)
• CAS DataBase Reference: 4-Methoxy-1H-Isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxy-1H-Isoindole-1,3(2H)-dione(41709-83-5)
• EPA Substance Registry System: 4-Methoxy-1H-Isoindole-1,3(2H)-dione(41709-83-5)

Safety Data

• Hazardous Substances Data: 41709-83-5(Hazardous Substances Data)

Usage

General Description

4-Methoxy-1H-Isoindole-1,3(2H)-dione, also known as 4-Methoxyphthalimide, is a chemical compound with the molecular formula C9H7NO4. It is a derivative of phthalimide and its structure consists of a phthalimide ring with a methoxy group attached to the benzene ring. 4-Methoxy-1H-Isoindole-1,3(2H)-dione is commonly used in organic synthesis as a precursor for the preparation of various pharmaceuticals, agrochemicals, and dyes. It is also used as a reagent in the synthesis of novel heterocyclic compounds. Additionally, 4-Methoxy-1H-Isoindole-1,3(2H)-dione has potential applications in the field of medicinal chemistry due to its ability to act as a building block for designing and synthesizing biologically active molecules.

Upstream product

• 14963-96-3 3-methoxyphthalic anhydride 
• 14963-97-4 3-methoxyphthalic acid 
• 57-13-6 urea 

Downstream Products

• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 127168-73-4 4-methoxy-1H-isoindole 

Relevant articles and documents

-

-

PHARMACEUTICAL COMBINATIONS

The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1- 5 hydrocarbyloxy; R4 is selected from hydrogen; a group -(O)n-R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 inhibitors.

PHARMACEUTICAL COMBINATIONS

The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group -(O)n-R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 and/or glycogen synthase kinase-3 and/or cyclin dependent kinase and/or aurora kinase inhibitors.